注射用氨磷汀对宫颈癌同步放化疗患者的保护作用  

Protective Effect of Amifostine on Cervical Cancer Patients Undergoing Concurrent Chemoradiotherapy

作　　者：李凤霜[1] 杜霄勐 宋芳[1] 韩超[1] 王建东[1] LI Fengshuang;DU Xiaomeng;SONG Fang;HAN Chao;WANG Jiandong(Department of Gynecologic Oncology,Beijing Obstetrics and Gynecology Hospital Affiliated to Capital Medical University,Beijing 100006,China)

机构地区：[1]首都医科大学附属北京妇产医院妇瘤科,北京100006

出　　处：《医学综述》2021年第7期1443-1447,共5页Medical Recapitulate

摘　　要：目的探索注射用氨磷汀对宫颈癌同步放化疗患者的保护作用。方法选取2017年3月至2018年3月首都医科大学附属北京妇产医院妇瘤科收治的经病理组织学检查确诊的57例宫颈癌患者为研究对象,随机分为对照组(28例)和试验组(29例)。两组均施行放疗同步顺铂化疗,试验组放疗前30 min予氨磷汀静脉滴注。观察两组同步放化疗完成情况以及不良反应发生情况。结果两组宫颈癌患者一般情况及同步放化疗完成情况比较差异无统计学意义(P>0.05)。试验组与对照组恶心呕吐≥G2、急性期腹泻≥G2的发生率比较差异无统计学意义(P>0.05)。试验组急性期骨髓抑制发生率明显低于对照组[31.0%(9/29)比57.1%(16/28)](P<0.05),且试验组白细胞计数最低值高于对照组[(2.9±1.5)×10^(9)/L比(2.1±1.4)×10^(9)/L](P<0.05);但两组血红蛋白及血小板计数最低值比较差异无统计学意义(P>0.05)。两组急性期皮肤反应≥G2的发生率比较差异无统计学意义(P>0.05),且两组均未发生3级及以上皮肤不良反应。结论在宫颈癌同步放化疗过程中,静脉输注氨磷汀可有效降低急性期血液学毒性,保证治疗进程,并有降低急性期腹泻发生率的趋势,但上消化道不良反应发生率可能轻度升高。Objective To explore the protective effect of amifostine for injection on cervical cancer patients with concurrent chemoradiotherapy.Methods A total of 57 patients with cervical cancer were selected from the Department of Gynecologic Oncology,Beijing Obstetrics and Gynecology Hospital Affiliated to Capital Medical University from Mar.2017 to Mar.2018,and were randomly divided into a control group(28 cases)and a test group(29 cases).Both groups were treated with radiotherapy concurrent with cisplatin chemotherapy,and the test group was given amifostine intravenously 30 minutes before radiotherapy.The completion of concurrent chemoradiotherapy and the occurrence of adverse reactions of the two groups were observed.Results There was no significant difference in the general situation and the completion of concurrent chemoradiotherapy between the two groups(P>0.05).There was no significant difference in the incidence of nausea and vomiting≥G2 and acute diarrhea≥G2 between the two groups(P>0.05).The incidence of acute myelosuppression in the test group was significantly lower than that in the control group[31.0%(9/29)vs 57.1%(16/28)](P<0.05),and the lowest white blood cell count in the test group was higher than that in the control group[(2.9±1.5)×10^(9)/L vs(2.1±1.4)×10^(9)/L](P<0.05),but there was no significant difference in the lowest hemoglobin and platelet count between the two groups(P>0.05).There was no significant difference in the incidence of acute skin reaction≥G2 between the two groups(P>0.05).Conclusion In the process of concurrent chemoradiotherapy for cervical cancer,intravenous infusion of amifostine can effectively reduce the hematological toxicity in the acute phase,ensure the treatment process,and reduce the incidence of diarrhea in the acute phase,but the incidence of adverse reactions in the upper digestive tract may be slightly increased.

关 键 词：宫颈癌 注射用氨磷汀 同步放化疗 

分 类 号：R711.74[医药卫生—妇产科学]